// App-Quantinova.ai

542 : LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Researchers

Presenter

  • Anthony R. Mato

Principal Investigators

  • Catherine C. Coombs

  • Nirav N. Shah

  • Nicole Lamanna

  • Ewa Lech-Maranda

  • Toby A. Eyre

  • Jennifer A. Woyach

  • William G. Wierda

  • Chan Yoon Cheah

  • Lindsey E Roeker

  • Manish R. Patel

  • Bita Fakhri

  • Minal Barve

  • Constantine S. Tam

  • David John Lewis

  • James N. Gerson

  • Alvaro J. Alencar

  • Justin Taylor

  • Omar Abdel-Wahab

  • Paolo Ghia

  • Stephen J. Schuster

  • Jessica Chen

  • Binoj Nair

  • Donald Tsai

  • Nora C. Ku

  • Matthew S. Davids

  • Jennifer R Brown

  • Wojciech Jurczak

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute,Seattle,Estados Unidos

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Med Coll of Wisconsin, Brookfield, WI

  • Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY

  • Department of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa,

  • Churchill Cancer Center, Oxford University Hospitals NHS Foundation Trust, Old Road, United Kingdom

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Linear Clinical Research/Sir Charles Gairdner Hospital, Nedlands, Australia

  • Florida Cancer Specialists and Research Institute, Sarasota, FL

  • Division of Rheumatology, University of California, San Francisco, CA

  • Mary Crowley Cancer Research Centers, Dallas, TX

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Plymouth Hospitals NHS Trust - Derriford Hospital ,Plymouth,United Kingdom

  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

  • Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • Loxo Oncology at Lilly,Stamford,USA

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Poland

  • United Kingdom

  • Australia

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B cell lymphomas

Biomarkers

  • Bruton tyrosine kinase

  • Progesterone receptor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Dose Escalation

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved